Long-Term Proton Pump Inhibitor Use in Children: A Retrospective Review of Safety
The objective of this work was to assess the efficacy of continuous proton pump inhibitor (PPI) therapy in children and to evaluate changes in biochemical, endoscopic, and histologic parameters during such treatment. A retrospective review of children receiving PPI therapy continuously for 1 year or...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases and sciences 2008-02, Vol.53 (2), p.385-393 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 393 |
|---|---|
| container_issue | 2 |
| container_start_page | 385 |
| container_title | Digestive diseases and sciences |
| container_volume | 53 |
| creator | Tolia, V. Boyer, K. |
| description | The objective of this work was to assess the efficacy of continuous proton pump inhibitor (PPI) therapy in children and to evaluate changes in biochemical, endoscopic, and histologic parameters during such treatment. A retrospective review of children receiving PPI therapy continuously for 1 year or more with baseline and follow-up esophageal and gastric biopsies on treatment was conducted to assess type, frequency, and duration of PPI dosing, symptom relief, gastrin levels, histologic findings, and adverse events. A total of 113 children (59 male, median age 4.5 years) were identified. Of these, 31% (35/113) were neurologically impaired. The median treatment duration was 35.2 months. Elevated serum gastrin levels occurred in 73% of children with no statistically significant differences in gastrin level by PPI type, dose, and dosing frequency or treatment duration. Adverse events were reported by 12% of children: diarrhea (5%) and constipation (4%) were the most frequent. Long-term PPI therapy appears to be effective, safe and well tolerated in children despite some biochemical, endoscopic, and histologic changes. |
| doi_str_mv | 10.1007/s10620-007-9880-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70233524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70233524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-5ff5c08debec9f97f81eecaa6b2a2a2fb46c95b7e9ba108fdc229518ebf9e1733</originalsourceid><addsrcrecordid>eNp1kFtrVDEUhYModlr9Ab5IENq3U3OZ3Hwrg5fCgFXb55CT2WlTzknG5JxK_30zzGBBkDxkbfLttXcWQu8oOaeEqI-VEslI12RntCadeoEWVCjeMSH1S7QgVDZNqTxCx7XeE0KMovI1OqJKKsmNXqAf65xuu2soI74qecoJX83jFl-mu9jHKRd8UwHHhFd3cdgUSJ_wBf4JU8l1C36KD9Cqhwh_cA74lwswPb5Br4IbKrw93Cfo5svn69W3bv396-XqYt15bszUiRCEJ3oDPXgTjAqaAnjnZM9cO6FfSm9Er8D0jhIdNp4xI6iGPhigivMTdLb33Zb8e4Y62TFWD8PgEuS5WkUY54ItG_jhH_A-zyW13SyjS86J0LJBdA_59rVaINhtiaMrj5YSuwvb7sO2O7kL26rW8_5gPPcjbJ47Duk24PQAuOrdEIpLPta_HCOUKKFp49ieq-0p3UJ53vD_058AugeWow</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214330586</pqid></control><display><type>article</type><title>Long-Term Proton Pump Inhibitor Use in Children: A Retrospective Review of Safety</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Tolia, V. ; Boyer, K.</creator><creatorcontrib>Tolia, V. ; Boyer, K.</creatorcontrib><description>The objective of this work was to assess the efficacy of continuous proton pump inhibitor (PPI) therapy in children and to evaluate changes in biochemical, endoscopic, and histologic parameters during such treatment. A retrospective review of children receiving PPI therapy continuously for 1 year or more with baseline and follow-up esophageal and gastric biopsies on treatment was conducted to assess type, frequency, and duration of PPI dosing, symptom relief, gastrin levels, histologic findings, and adverse events. A total of 113 children (59 male, median age 4.5 years) were identified. Of these, 31% (35/113) were neurologically impaired. The median treatment duration was 35.2 months. Elevated serum gastrin levels occurred in 73% of children with no statistically significant differences in gastrin level by PPI type, dose, and dosing frequency or treatment duration. Adverse events were reported by 12% of children: diarrhea (5%) and constipation (4%) were the most frequent. Long-term PPI therapy appears to be effective, safe and well tolerated in children despite some biochemical, endoscopic, and histologic changes.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-007-9880-7</identifier><identifier>PMID: 17676398</identifier><identifier>CODEN: DDSCDJ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage ; Biochemistry ; Biological and medical sciences ; Child ; Child, Preschool ; Digestive system ; Esophagitis - blood ; Esophagitis - drug therapy ; Female ; Gastrins - blood ; Gastroenterology ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatology ; Humans ; Lansoprazole ; Liver Function Tests ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Omeprazole - administration & dosage ; Oncology ; Original Paper ; Other diseases. Semiology ; Pharmacology. Drug treatments ; Proton Pump Inhibitors - administration & dosage ; Rabeprazole ; Retrospective Studies ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Transplant Surgery ; Vitamin B 12 - blood</subject><ispartof>Digestive diseases and sciences, 2008-02, Vol.53 (2), p.385-393</ispartof><rights>Springer Science+Business Media, LLC 2007</rights><rights>2008 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-5ff5c08debec9f97f81eecaa6b2a2a2fb46c95b7e9ba108fdc229518ebf9e1733</citedby><cites>FETCH-LOGICAL-c399t-5ff5c08debec9f97f81eecaa6b2a2a2fb46c95b7e9ba108fdc229518ebf9e1733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10620-007-9880-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10620-007-9880-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20107581$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17676398$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tolia, V.</creatorcontrib><creatorcontrib>Boyer, K.</creatorcontrib><title>Long-Term Proton Pump Inhibitor Use in Children: A Retrospective Review of Safety</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>The objective of this work was to assess the efficacy of continuous proton pump inhibitor (PPI) therapy in children and to evaluate changes in biochemical, endoscopic, and histologic parameters during such treatment. A retrospective review of children receiving PPI therapy continuously for 1 year or more with baseline and follow-up esophageal and gastric biopsies on treatment was conducted to assess type, frequency, and duration of PPI dosing, symptom relief, gastrin levels, histologic findings, and adverse events. A total of 113 children (59 male, median age 4.5 years) were identified. Of these, 31% (35/113) were neurologically impaired. The median treatment duration was 35.2 months. Elevated serum gastrin levels occurred in 73% of children with no statistically significant differences in gastrin level by PPI type, dose, and dosing frequency or treatment duration. Adverse events were reported by 12% of children: diarrhea (5%) and constipation (4%) were the most frequent. Long-term PPI therapy appears to be effective, safe and well tolerated in children despite some biochemical, endoscopic, and histologic changes.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage</subject><subject>Biochemistry</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Digestive system</subject><subject>Esophagitis - blood</subject><subject>Esophagitis - drug therapy</subject><subject>Female</subject><subject>Gastrins - blood</subject><subject>Gastroenterology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Lansoprazole</subject><subject>Liver Function Tests</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Omeprazole - administration & dosage</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Other diseases. Semiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Proton Pump Inhibitors - administration & dosage</subject><subject>Rabeprazole</subject><subject>Retrospective Studies</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Transplant Surgery</subject><subject>Vitamin B 12 - blood</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kFtrVDEUhYModlr9Ab5IENq3U3OZ3Hwrg5fCgFXb55CT2WlTzknG5JxK_30zzGBBkDxkbfLttXcWQu8oOaeEqI-VEslI12RntCadeoEWVCjeMSH1S7QgVDZNqTxCx7XeE0KMovI1OqJKKsmNXqAf65xuu2soI74qecoJX83jFl-mu9jHKRd8UwHHhFd3cdgUSJ_wBf4JU8l1C36KD9Cqhwh_cA74lwswPb5Br4IbKrw93Cfo5svn69W3bv396-XqYt15bszUiRCEJ3oDPXgTjAqaAnjnZM9cO6FfSm9Er8D0jhIdNp4xI6iGPhigivMTdLb33Zb8e4Y62TFWD8PgEuS5WkUY54ItG_jhH_A-zyW13SyjS86J0LJBdA_59rVaINhtiaMrj5YSuwvb7sO2O7kL26rW8_5gPPcjbJ47Duk24PQAuOrdEIpLPta_HCOUKKFp49ieq-0p3UJ53vD_058AugeWow</recordid><startdate>20080201</startdate><enddate>20080201</enddate><creator>Tolia, V.</creator><creator>Boyer, K.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20080201</creationdate><title>Long-Term Proton Pump Inhibitor Use in Children: A Retrospective Review of Safety</title><author>Tolia, V. ; Boyer, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-5ff5c08debec9f97f81eecaa6b2a2a2fb46c95b7e9ba108fdc229518ebf9e1733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage</topic><topic>Biochemistry</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Digestive system</topic><topic>Esophagitis - blood</topic><topic>Esophagitis - drug therapy</topic><topic>Female</topic><topic>Gastrins - blood</topic><topic>Gastroenterology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Lansoprazole</topic><topic>Liver Function Tests</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Omeprazole - administration & dosage</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Other diseases. Semiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Proton Pump Inhibitors - administration & dosage</topic><topic>Rabeprazole</topic><topic>Retrospective Studies</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Transplant Surgery</topic><topic>Vitamin B 12 - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tolia, V.</creatorcontrib><creatorcontrib>Boyer, K.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tolia, V.</au><au>Boyer, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Proton Pump Inhibitor Use in Children: A Retrospective Review of Safety</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2008-02-01</date><risdate>2008</risdate><volume>53</volume><issue>2</issue><spage>385</spage><epage>393</epage><pages>385-393</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><coden>DDSCDJ</coden><abstract>The objective of this work was to assess the efficacy of continuous proton pump inhibitor (PPI) therapy in children and to evaluate changes in biochemical, endoscopic, and histologic parameters during such treatment. A retrospective review of children receiving PPI therapy continuously for 1 year or more with baseline and follow-up esophageal and gastric biopsies on treatment was conducted to assess type, frequency, and duration of PPI dosing, symptom relief, gastrin levels, histologic findings, and adverse events. A total of 113 children (59 male, median age 4.5 years) were identified. Of these, 31% (35/113) were neurologically impaired. The median treatment duration was 35.2 months. Elevated serum gastrin levels occurred in 73% of children with no statistically significant differences in gastrin level by PPI type, dose, and dosing frequency or treatment duration. Adverse events were reported by 12% of children: diarrhea (5%) and constipation (4%) were the most frequent. Long-term PPI therapy appears to be effective, safe and well tolerated in children despite some biochemical, endoscopic, and histologic changes.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>17676398</pmid><doi>10.1007/s10620-007-9880-7</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-2116 |
| ispartof | Digestive diseases and sciences, 2008-02, Vol.53 (2), p.385-393 |
| issn | 0163-2116 1573-2568 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70233524 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage Biochemistry Biological and medical sciences Child Child, Preschool Digestive system Esophagitis - blood Esophagitis - drug therapy Female Gastrins - blood Gastroenterology Gastroenterology. Liver. Pancreas. Abdomen Hepatology Humans Lansoprazole Liver Function Tests Male Medical sciences Medicine Medicine & Public Health Omeprazole - administration & dosage Oncology Original Paper Other diseases. Semiology Pharmacology. Drug treatments Proton Pump Inhibitors - administration & dosage Rabeprazole Retrospective Studies Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Transplant Surgery Vitamin B 12 - blood |
| title | Long-Term Proton Pump Inhibitor Use in Children: A Retrospective Review of Safety |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T18%3A30%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Proton%20Pump%20Inhibitor%20Use%20in%20Children:%20A%20Retrospective%20Review%20of%20Safety&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Tolia,%20V.&rft.date=2008-02-01&rft.volume=53&rft.issue=2&rft.spage=385&rft.epage=393&rft.pages=385-393&rft.issn=0163-2116&rft.eissn=1573-2568&rft.coden=DDSCDJ&rft_id=info:doi/10.1007/s10620-007-9880-7&rft_dat=%3Cproquest_cross%3E70233524%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214330586&rft_id=info:pmid/17676398&rfr_iscdi=true |